• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

结直肠癌和黑色素瘤中的KRAS、NRAS及BRAF突变

KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.

作者信息

Cicenas Jonas, Tamosaitis Linas, Kvederaviciute Kotryna, Tarvydas Ricardas, Staniute Gintare, Kalyan Karthik, Meskinyte-Kausiliene Edita, Stankevicius Vaidotas, Valius Mindaugas

机构信息

Vetsuisse Faculty, Institute of Animal Pathology, University of Bern, 3012, Bern, Switzerland.

MAP Kinase Resource, Bern, Switzerland.

出版信息

Med Oncol. 2017 Feb;34(2):26. doi: 10.1007/s12032-016-0879-9. Epub 2017 Jan 10.

DOI:10.1007/s12032-016-0879-9
PMID:28074351
Abstract

Cancers are the group of diseases, which arise because of the uncontrolled behavior of some of the genes in our cells. There are possibilities of gene amplifications, overexpressions, deletions and other anomalies which might lead to the development and spread of cancer. One of the most dangerous ways to the cancers is the mutations of the genes. The mutated genes can start unstoppable proliferation of cells, their uncontrolled motility, protection from apoptosis, the DNA mutation enhancement as well as other anomalies, leading to the cancer. This review focuses on the genes, which are frequently mutated in various cancers and are known to be important in the advance and progression of colorectal cancer and melanoma, namely KRAS, NRAS and BRAF.

摘要

癌症是一组疾病,其产生是由于我们细胞中的某些基因出现不受控制的行为。存在基因扩增、过度表达、缺失及其他异常情况的可能性,这些可能导致癌症的发生和扩散。导致癌症最危险的途径之一是基因的突变。突变的基因可引发细胞不可阻挡的增殖、不受控制的移动性、对细胞凋亡的抵抗、DNA突变增强以及其他异常情况,从而导致癌症。本综述聚焦于在各种癌症中频繁发生突变且已知在结直肠癌和黑色素瘤的进展中起重要作用的基因,即KRAS、NRAS和BRAF。

相似文献

1
KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.结直肠癌和黑色素瘤中的KRAS、NRAS及BRAF突变
Med Oncol. 2017 Feb;34(2):26. doi: 10.1007/s12032-016-0879-9. Epub 2017 Jan 10.
2
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.KRAS、NRAS、BRAF和PIK3CA突变对原发性结直肠癌的预后影响:一项基于人群的研究。
J Transl Med. 2016 Oct 13;14(1):292. doi: 10.1186/s12967-016-1053-z.
3
Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes.通过对KRAS、NRAS和BRAF癌基因进行常规分析检测罕见突变
Bull Exp Biol Med. 2017 Jan;162(3):375-378. doi: 10.1007/s10517-017-3619-z. Epub 2017 Jan 14.
4
Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.桥连核酸夹实时 PCR 法检测转移性结直肠癌中的 KRAS、NRAS 和 BRAF 突变
BMC Med Genomics. 2019 Nov 11;12(1):162. doi: 10.1186/s12920-019-0610-8.
5
Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?基于 CT 的放射组学特征能否预测结直肠癌中的 KRAS/NRAS/BRAF 突变?
Eur Radiol. 2018 May;28(5):2058-2067. doi: 10.1007/s00330-017-5146-8. Epub 2018 Jan 15.
6
PIK3CA Mutated Colorectal Cancers Without KRAS, NRAS and BRAF Mutations Possess Common and Potentially Targetable Mutations in Epigenetic Modifiers and DNA Damage Response Genes.PIK3CA 突变而 KRAS、NRAS 和 BRAF 无突变的结直肠癌存在表观遗传修饰和 DNA 损伤反应基因的常见潜在可靶向突变。
Cancer Genomics Proteomics. 2024 Sep-Oct;21(5):533-548. doi: 10.21873/cgp.20470.
7
KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study.希腊和罗马尼亚结直肠癌患者的KRAS、NRAS和BRAF基因突变:一项队列研究。
BMJ Open. 2014 May 23;4(5):e004652. doi: 10.1136/bmjopen-2013-004652.
8
Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.印度结直肠癌患者中KRAS、BRAF、PIK3CA、NRAS、TP53和APC基因突变的患病率及共存情况:基于二代测序的队列研究
Tumour Biol. 2017 Feb;39(2):1010428317692265. doi: 10.1177/1010428317692265.
9
Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.转移性结直肠癌中同时存在 NRAS-BRAF 变异:一例突尼斯病例报告。
Anticancer Drugs. 2024 Jun 1;35(5):462-465. doi: 10.1097/CAD.0000000000001586. Epub 2024 Mar 5.
10
Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.原发性和转移性结直肠癌中神经内分泌分化与KRAS/NRAS/BRAF/PIK3CA/TP53突变状态的比较
Int J Clin Exp Pathol. 2014 Aug 15;7(9):5927-39. eCollection 2014.

引用本文的文献

1
Melanoma and Colorectal Cancer as Second Primary Cancers: A Scoping Review of Their Association and the Underlying Biological, Lifestyle, and Genetic Factors.黑色素瘤和结直肠癌作为第二原发性癌症:对其关联以及潜在生物学、生活方式和遗传因素的范围综述
J Gastrointest Cancer. 2025 May 31;56(1):125. doi: 10.1007/s12029-024-01114-7.
2
RIPK2 promotes colorectal cancer metastasis by protecting YAP degradation from ITCH-mediated ubiquitination.RIPK2通过保护YAP不被ITCH介导的泛素化降解来促进结直肠癌转移。
Cell Death Dis. 2025 Apr 4;16(1):248. doi: 10.1038/s41419-025-07599-9.
3
Rethinking AMPK: A Reversible Switch Fortifying Cancer Cell Stress-Resilience.

本文引用的文献

1
Multi-kinase inhibitors, AURKs and cancer.多激酶抑制剂、极光激酶与癌症
Med Oncol. 2016 May;33(5):43. doi: 10.1007/s12032-016-0758-4. Epub 2016 Apr 1.
2
The Aurora kinase inhibitors in cancer research and therapy.癌症研究与治疗中的极光激酶抑制剂。
J Cancer Res Clin Oncol. 2016 Sep;142(9):1995-2012. doi: 10.1007/s00432-016-2136-1. Epub 2016 Mar 1.
3
Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.非小细胞肺癌中枢神经系统转移患者中MEK1基因突变筛查的灵敏方法。
重新审视AMPK:强化癌细胞应激恢复力的可逆开关
Yale J Biol Med. 2025 Mar 31;98(1):33-52. doi: 10.59249/JKBB6336. eCollection 2025 Mar.
4
Facts, Dogmas, and Unknowns About Mitochondrial Reactive Oxygen Species in Cancer.关于癌症中线粒体活性氧的事实、教条与未知
Antioxidants (Basel). 2024 Dec 19;13(12):1563. doi: 10.3390/antiox13121563.
5
Exploring somatic mutations in , , and as therapeutic targets in Saudi colorectal cancer patients through massive parallel sequencing and variant classification.通过大规模平行测序和变异分类探索沙特结直肠癌患者中、和的体细胞突变作为治疗靶点。 (注:原文中三个“,”处内容缺失,导致句子翻译出来有些不完整,但根据要求按给定原文进行了翻译)
Front Pharmacol. 2024 Nov 20;15:1498295. doi: 10.3389/fphar.2024.1498295. eCollection 2024.
6
Unveiling the role of in Chinese colorectal cancer patients: a positive influence on tumor mutational burden.揭示[具体内容]在中国结直肠癌患者中的作用:对肿瘤突变负荷的积极影响。 (原文中“Unveiling the role of ”后缺少具体内容)
Transl Cancer Res. 2024 Sep 30;13(9):4752-4762. doi: 10.21037/tcr-24-600. Epub 2024 Sep 25.
7
Exploring the multifaceted role of RASGRP1 in disease: immune, neural, metabolic, and oncogenic perspectives.探讨 RASGRP1 在疾病中的多方面作用:免疫、神经、代谢和致癌角度。
Cell Cycle. 2024 Mar;23(6):722-746. doi: 10.1080/15384101.2024.2366009. Epub 2024 Jun 12.
8
Tumor- and Fibroblast-Derived Cell-Free DNAs Differently Affect the Progression of B16 Melanoma In Vitro and In Vivo.肿瘤细胞和成纤维细胞来源的无细胞 DNA 对体外和体内 B16 黑色素瘤进展的影响不同。
Int J Mol Sci. 2024 May 13;25(10):5304. doi: 10.3390/ijms25105304.
9
Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression.病例报告:多线治疗进展后,使用达拉非尼和曲美替尼联合治疗携带BRCA2胚系突变的BRAF V600E突变型肺腺癌
Front Oncol. 2024 Apr 23;14:1387388. doi: 10.3389/fonc.2024.1387388. eCollection 2024.
10
Determination of the Prevalence of Microsatellite Instability, and / Mutation Status in Patients with Colorectal Cancer in Slovakia.斯洛伐克结直肠癌患者微卫星不稳定性及突变状态患病率的测定
Cancers (Basel). 2024 Mar 12;16(6):1128. doi: 10.3390/cancers16061128.
Clin Transl Oncol. 2016 Oct;18(10):1039-43. doi: 10.1007/s12094-016-1483-3. Epub 2016 Feb 9.
4
Sar1 GTPase Activity Is Regulated by Membrane Curvature.Sar1 GTP酶活性受膜曲率调节。
J Biol Chem. 2016 Jan 15;291(3):1014-27. doi: 10.1074/jbc.M115.672287. Epub 2015 Nov 6.
5
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.达拉非尼联合曲美替尼与维莫非尼单药治疗不可切除或转移性皮肤 BRAF Val600 突变阳性黑色素瘤患者的健康相关生活质量比较(COMBI-v):一项开放标签、随机、3 期临床试验结果。
Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X.
6
Roscovitine in cancer and other diseases.罗可丁在癌症及其他疾病中的应用。
Ann Transl Med. 2015 Jun;3(10):135. doi: 10.3978/j.issn.2305-5839.2015.03.61.
7
Increased expression of ARF GTPases in prostate cancer tissue.前列腺癌组织中ARF GTP酶表达增加。
Springerplus. 2015 Jul 12;4:342. doi: 10.1186/s40064-015-1136-y. eCollection 2015.
8
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.达拉非尼联合曲美替尼与达拉非尼联合安慰剂治疗 Val600BRAF 突变型黑色素瘤:一项多中心、双盲、III 期随机对照临床试验。
Lancet. 2015 Aug 1;386(9992):444-51. doi: 10.1016/S0140-6736(15)60898-4. Epub 2015 May 31.
9
Structures of Ras superfamily effector complexes: What have we learnt in two decades?Ras 超家族效应器复合物的结构:二十年来我们学到了什么?
Crit Rev Biochem Mol Biol. 2015 Mar-Apr;50(2):85-133. doi: 10.3109/10409238.2014.999191. Epub 2015 Apr 1.
10
Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma.BRAF 突变与原发性黑色素瘤临床病理特征的荟萃分析
J Am Acad Dermatol. 2015 Jun;72(6):1036-46.e2. doi: 10.1016/j.jaad.2015.02.1113. Epub 2015 Mar 25.